Neuraxis declares Q2 stock dividend on Series B preferred

Neuraxis, Inc. reported that its Board of Directors authorized and the company declared a stock dividend on its Series B Preferred Stock for the second quarter of 2026.

Rhea-AI Filing Summary

Neuraxis, Inc. reported that its Board of Directors authorized and the company declared a stock dividend on its Series B Preferred Stock for the second quarter of 2026. This dividend will be paid in shares of Neuraxis common stock.

The number of common shares each Series B holder receives will equal that holder’s accrued and unpaid dividends from April 1, 2026 through the record date, divided by $2.38. A total of approximately 80,463 shares of common stock are expected to be issued. The dividend is payable on July 29, 2026 to Series B holders of record as of the close of business on July 21, 2026. No fractional shares will be issued; instead, any fractional entitlement will be settled in cash using the same $2.38 figure.

Insights

Equity & Capital Structure Analyst

Small common-share issuance to satisfy preferred stock dividend.

Neuraxis is paying the second-quarter dividend on its Series B Preferred Stock in common shares instead of cash, using a per-share conversion figure of $2.38. The company expects to issue about 80,463 common shares for this purpose.

This approach preserves cash while modestly increasing the common share count. The practical impact depends on the existing number of common shares outstanding, which determines how dilutive this issuance is for common shareholders. Preferred holders receive value tied to accrued and unpaid dividends through July 21, 2026.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Key Figures

Expected common shares issued: approximately 80,463 shares of Common Stock Dividend conversion figure: $2.38 Par value common stock: $0.001 per share +3 more

6 metrics

Expected common shares issued approximately 80,463 shares of Common Stock Expected issuance in connection with the Second Quarter 2026 dividend on Series B Preferred Stock

Dividend conversion figure $2.38 Accrued and unpaid dividends divided by $2.38 to determine common shares issued

Par value common stock $0.001 per share Par value of Neuraxis common stock used for the stock dividend

Par value Series B Preferred Stock $0.001 per share Par value of Neuraxis Series B Preferred Stock receiving the dividend

Dividend record date July 21, 2026 Holders of Series B Preferred Stock of record as of close of business on this date receive the dividend

Dividend payment date July 29, 2026 Date the Second Quarter 2026 stock dividend will be paid

Key Terms

stock dividend, Series B Preferred Stock, record date, fractional shares

4 terms

stock dividend financial

"authorized and the Company declared a stock dividend on the Company’s Series B Preferred Stock"

A stock dividend is when a company gives its existing shareholders extra shares instead of cash. It’s like receiving more pieces of the same pie rather than a bigger piece of money, which can increase the number of shares you own but usually doesn’t change the total value of your investment right away. Investors care about it because it can signal the company's growth and affect the stock’s price.

Series B Preferred Stock financial

"stock dividend on the Company’s Series B Preferred Stock, par value $0.001 per share"

Series B preferred stock is a type of ownership share issued by a company that offers certain advantages over common stock, such as priority in receiving dividends or assets if the company is sold or liquidated. It is typically issued after an initial round of funding, making it a way for investors to support a company's growth while gaining some protections and benefits. This stock matters to investors because it often provides a more secure investment position with potential for future growth.

record date financial

"from April 1, 2026 through the record date, divided by $2.38"

The record date is the specific day when a company determines which shareholders are eligible to receive a dividend or participate in an upcoming vote. It’s like a cutoff date; if you own the stock on that day, you get the benefits or voting rights. This date matters because it decides who qualifies for certain company benefits.

fractional shares financial

"No fractional shares will be issued in connection with the Second Quarter Dividend"

Fractional shares are portions of a whole share of a stock or fund, allowing investors to own less than one full unit. They make it possible to invest a specific dollar amount rather than buy whole shares, like buying a slice of a pizza instead of the entire pie. For investors this lowers the cost barrier, helps with diversification, and lets you reinvest dividends or purchase expensive stocks in small, precise amounts.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Neuraxis (NRXS) announce regarding its Series B Preferred Stock dividend?

Neuraxis announced a second-quarter 2026 dividend on its Series B Preferred Stock, to be paid in shares of its common stock rather than cash, based on accrued and unpaid dividends through the record date.

How many Neuraxis (NRXS) common shares are expected to be issued for the Second Quarter Dividend?

Neuraxis expects to issue approximately 80,463 shares of common stock to satisfy the second-quarter 2026 dividend obligations on its Series B Preferred Stock, with the exact amount driven by accrued and unpaid dividends.

How is the Neuraxis (NRXS) stock dividend on Series B Preferred Stock calculated?

Each holder’s stock dividend is calculated by taking accrued and unpaid dividends on that holder’s Series B Preferred Stock from April 1, 2026 through the record date, and dividing that amount by $2.38 to determine common shares received.

When is the record date and payment date for Neuraxis (NRXS) Second Quarter Dividend?

The stock dividend will be paid on July 29, 2026 to holders of Neuraxis Series B Preferred Stock of record as of the close of business on July 21, 2026.

>How will Neuraxis (NRXS) handle fractional shares from the stock dividend?

Neuraxis will not issue fractional common shares. Instead, Series B holders entitled to a fraction will receive cash equal to $2.38 multiplied by the fractional share amount, without interest or deductions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/10/2026 - 07:00 AM Learn about SEC filing dates

false 0001933567 0001933567 2026-07-09 2026-07-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): July 9, 2026

Neuraxis, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-41775		45-5079684
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

11611 N. Meridian St, Suite 330 

Carmel, IN 46032

(Address of principal executive offices)

Registrant’s telephone number, including area code: (812) 689-0791

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value		NRXS		NYSE American

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events

On July 9, 2026, the Board of Directors of Neuraxis, Inc. (the “Company”) authorized and the Company declared a stock dividend on the Company’s Series B Preferred Stock, par value $0.001 per share (the “Series B Preferred Stock”) for the second quarter of 2026 (the “Second Quarter Dividend”). The Second Quarter Dividend will be paid in the form of shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”). The number of shares of Common Stock to be received by each holder will be determined based on the accrued and unpaid dividends on such holder’s Series B Preferred Stock from April 1, 2026 through the record date, divided by $2.38. A total of approximately 80,463 shares of Common Stock are expected to be issued in connection with the Second Quarter Dividend. No fractional shares will be issued in connection with the Second Quarter Dividend. In lieu of any fractional shares, holders of Series B Preferred Stock who would otherwise be entitled to receive a fractional share of Common Stock will receive cash (without interest or deduction) in an amount equal to the product obtained by multiplying (a) $2.38 by (b) the fraction of one share of Series B Preferred Stock owned by such holder. The Second Quarter Dividend will be payable on July 29, 2026, to holders of record of the Company’s Series B Preferred Stock as of the close of business on July 21, 2026.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: July 10, 2026	NEURAXIS, INC.
	By:	/s/ Brian Carrico
	Name:	Brian Carrico
	Title:	President and Chief Executive Officer

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL SCHEMA FILE 2.9 KB
• EX-101 XBRL LABEL FILE 33.4 KB
• EX-101 XBRL PRESENTATION FILE 21.8 KB